Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.

Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C. · 2023

Read Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. by Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10029244.txt.

Introduction

Zhang and co-workers review the roles of tumor-linked macrophages in checkpoint immunotherapy for solid cancers, in a 2023 paper. Checkpoint drugs free T cells to attack tumors, yet only a small share of patients gains lasting benefit. The cells around the tumor, including macrophages, help decide who responds.

The review explains how these macrophages can block or aid the drugs' effects. It surveys ways to reprogram them, such as blocking their signals or clearing them out. The authors argue that pairing such steps with checkpoint drugs could widen the circle of patients who benefit.

Catalog record

CREATORZhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE114 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10029244

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers By Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu, Chengzeng Wang Published in: Molecular Cancer DOI: 10.1186/s12943-023-01725-x ABSTRACT Abstract In recent years, tumor immunotherapy has made significant progress. However, tumor immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of patients in solid cancers. The tumor microenvironment (TME) acts a significant role in tumor immunotherapy. Studies reported that tumor-associated macrophages (TAMs), as one of the main components of TME, seriously affected the therapeutic effect of PD-1/PD-L1 inhibitors. In this review, we analyzed TAMs from epigenetic and single-cell perspectives and introduced the role and mechanisms of TAMs in anti-programmed death protein 1(anti-PD-1) therapy. In addition, we summarized combination regimens that enhance the efficacy of tumor PD-1/PD-L1 inhibitors and elaborated on the role of the TAMs in different solid cancers. Eventually, the clinical value of TAMs by influencing the therapeutic effect of tumor PD-1/PD-L1 inhibitors was discussed. These above are beneficial to elucidate poor therapeutic effect of PD-1/PD-L1 inhibitors in solid tumors from the point of view of TAMs and explore the strategies to improve its objective remission rate of solid cancers. Keywords: Tumor-associated macrophages, Immune checkpoint inhibitors, Cancer, Combined therapy BACKGROUND Since the US Food and Drug Administration approved ipilimumab (anti-CTLA-4) for the treatment of metastatic melanoma in 2011 [1], several checkpoint-blocking therapies targeting the PD-1/PD-L1 axis have been approved for the treatment of multiple tumor types. A good understanding of the impact of the tumor microenvironment(TME) on tumor immunotherapy is essential for effectively integrating immunotherapy with chemotherapy, targeted therapy, and other immunotherapies. Studies have shown that tumor-associated macrophages (TAMs) act a crucial role in tumor immunotherapy [2]. TAMs affect the therapeutic effect of PD-1/PD-L1 inhibitors through various mechanisms, including regulating the expression of PD-L1 in tumor cells and secreting a variety of cytokines to produce tumor-promoting TME [3–5]. Chemotherapy, targeted therapy, and radiotherapy effectively remodel TME, especially TAMs, and transform them from pro-tumor to antitumor [6–8]. In this review, we summarized the currently approved immune checkpoint inhibitors (ICIs) (Table 1) and the role of TAMs in anti-PD-1/PD-L1 treatment for solid cancers [9–16]. We described the synergistic effects of anti-PD-1/PD-L1 therapy in combination with targeted therapy, chemotherapy, radiotherapy, and other immunotherapies. The mechanism of the impact of TAMs on immunotherapy in different solid cancers was also concluded. Furthermore, the clinical application value of TAMs for the solid cancer treatment of PD-1/PD-L1 inhibitors is proposed based on the vital role of TAMs in immunotherapy. [Table: The approved immune checkpoint inhibitors in the globe] TAMS AND TME TME contains not only tumor cells but also innate and adaptive immune cells, fibroblasts, endothelial cells, pericytes, and non-cellular components such as extracellular matrix and soluble signals that infiltrate the tumor [17, 18]. TME is reportedly deeply associated with tumor tissue formation, survival, and metastasis [19, 20]. TAMs are the most plasticity and the highest proportion of immune cells in the TME [21]. TAMs were generally classified into two main phenotypes: classical activation (M1-like macrophages) and alternating activation (M2-like macrophages) [22]. M1-like macrophages are low in mannose receptor (CD206) and high expression of MHCII. M1-like macrophages are characterized by increased expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor-α(TNF-α), and co-stimulatory molecules such as CD40, CD86, and various pro-inflammatory cytokines such as IL6, IL1b, IL12a, IL12b. M1-like macrophages induce antitumor immune responses through their T cell stimulating activity [23, 24]. TAMs were polarized to the M2 type under the induction of a variety of mediators, including IL-4, IL-10, transforming growth factor-β (TGF-β), and macrophage colony-stimulating factor (M-CSF) [24, 25]. Unlike M1, CD163+ is characteristic of M2-like macrophages, which express high mannose receptors and low levels of MHC II and release immunosuppressive cytokines such as vascular endothelial growth factor (VEGF) and arginase 1 (Arg-1), IL-10, TGF-β, indolamine 2,3-dioxygenase (IDO). In terms of cell function, M2-like macrophages promote tumor immune evasion, angiogenesis, tumor growth and metastasis [26–32]. Increasing evidences suggest that TAMs play a significant role in tumor development. TAMs directly communicate with tumor cells. On the one hand, TAMs affect tumor cells through exosome metastasis of substances like some non-coding RNAs(ncRNAs) [33]. TAMs-derived miR-223 is vital for breast cancer progression. Similarly, both miR-21-5p and miR-155-5p act essential roles in the migration and invasion processes of colon cancer cells [34]. In addition, lncRNA SBF2-AS1 absorbed by pancreatic cancer cells also promotes tumor proliferation, invasion, and migration [35]. Parallelly, the TAMs-derived VEGF and miR-501-3p directly mediate the angiogenesis in the tumor tissues [36, 37]. Furthermore, the miR-365 exosomes inhibit the effects of gemcitabine by upregulating pyrimidine metabolism and increasing nucleotide triphosphate levels in cancer cells [38]. On the other hand, TAMs secrete various cytokines that act on tumor cells. For example, TNF, IL-6, and IFN- γ upregulate PD-L1 expression in tumor cells. Indirect effects of TAMs on tumor cells are achieved by influencing other immune cells to regulate the TME. TAMs directly inhibit CD8+ T-cell proliferation through the metabolism of L-arginine via Arg-1, iNOS, and oxygen radicals [39, 40]. TAMs also induce T cell inhibition by the immune checkpoint through upregulation of PD-L1 expression. Moreover, TAMs recruit Tregs through CCL22 to further inhibit the antitumor immune response of T cells [41]. M2-polarized TAMs release a variety of anti-inflammatory cytokines (e. g., TGFB1) and chemokines (e. g., CCL22) that inhibit dendritic cell maturation and thus limit antigen presentation [41]. Evidently, TAMs create a TME suitable for tumor growth by suppressing the antitumor activity of immune cells. Inversely, when TAMs are polarized to M1, they directly mediate cytotoxicity to kill tumor cells. In this case, macrophages release tumor-killer molecules, such as reactive oxygen species (ROS) and NO, which have cytotoxic effects on tumor cells [42]. The other is antibody-dependent cell-mediated cytotoxicity killing of tumor cells that requires the involvement of antitumor antibodies [43]. At the same time, the effect of TAMs on cancer cells is not unidirectional. Tumor cells also regulate TAMs to exert an immunosuppressive function through multiple mechanisms. For example, colony-stimulating factor 1 (CSF1) secreted by tumor cells favors the recruitment of monocyte-derived macrophages to the TME and polarizes them to the M2-like manner [44]. Moreover, lactate produced due to the high metabolism of tumor cells promotes M2 polarization of TAMs [45]. Consequently, TAMs build a complex immune regulatory network through various signaling mechanisms and other cells in the TME (Fig. 1). [Figure: The role of TAMs in TME. Exosomes derived from TAMs deliver various molecules into tumor cells, which contributes to tumor development. Exosomal lncRNA SBF2-AS1 facilitates tumor cell proliferation. Exosomal miR-223 and miR-21-5p promote the metastasis of tumor cells from the primary tumor to the distal organs. Exosomal miR-501-3p promotes the angiogenesis of tumors. Exosomal miR-223 and miR-365 help tumor cells develop resistance to chemotherapy. TAMs express ligand receptors for PD-1 and CTLA-4, inhibiting the cytotoxic function of T cells, NK cells, and NK cells upon activation. TAMs express chemokine CCL22, etc., to recruit Treg cells. TAMs secrete VEGF to promote angiogenesis in TME. TAMs release a variety of anti-inflammatory cytokines to inhibit dendritic cell maturation, thereby limiting antigen presentation. In addition, tumor cells affect TAMs polarization by releasing exosomes, cytokines and their metabolites]

Read the complete text